I have had the honor and privilege to interview Alfred E. Mann, CEO of Mannkind corp. I want to thank him for taking time from his busy schedule. This is an original interview and has not been posted anywhere else. I received his written answers on June 3rd 2010.
This June is a crucial month for Mannkind. The company is meeting with the FDA to address the issues raised in the complete response letter and the submission of additional data, that includes the bio-equivalency data for dreamboat inhaler.